StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen other Revenues (Royalties, Milestone & Collaboration Revenues) — Worldwide ($M) ($M)

Form 10-Q / 10-K Consolidated Statements of Income & Note 2 (XBRL)

Latest, FY2025
1,603
Period ended Dec 31, 2025
Change on a year earlier
+14.7%
1,398 in FY2024
History
11 years
Since FY2015
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Revenues (Royalties, Milestone & Collaboration Revenues) — Worldwide ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,603+14.7%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 20241,398+9.2%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 20231,280-15.9%Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 20221,522-9.5%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 20211,682+42.1%Form 10-K (filed 2024-02-14) ↗
FY2020Dec 31, 20201,184+2.2%Form 10-K (filed 2023-02-09) ↗
FY2019Dec 31, 20191,158-4.6%Form 10-K (filed 2022-02-16) ↗
FY2018Dec 31, 20181,214+15.2%Form 10-K (filed 2021-02-09) ↗
FY2017Dec 31, 20171,054-4.1%Form 10-K (filed 2019-02-13) ↗
FY2016Dec 31, 20161,099+53.1%Form 10-K (filed 2019-02-13) ↗
FY2015Dec 31, 2015718–Form 10-K (filed 2018-02-13) ↗

Breakdown

What makes up other revenues (royalties, milestone & collaboration revenues) — worldwide ($m)

Cite this data

StockData. (2026). Amgen Other Revenues (Royalties, Milestone & Collaboration Revenues) — Worldwide ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/rev_other_ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.